Formulation Development
FORMULATION DEVELOPMENT WHITE PAPERS & ARTICLES
-
Why Emerging Drug Developers Can't Afford To Delay Analytical Development
Rushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.
-
Polymorphism 101: What Early-Stage Drug Developers Need To Know To Reduce Risk
Polymorphism impacts solubility, stability, and manufacturability, making early solid‑form screening critical to reduce risk, guide development decisions, and ensure consistent performance.
-
How Peptides Became Cornerstones Of Modern Medicine
Peptides evolved from early chemical discoveries to transformative therapies, culminating in GLP‑1 drugs that highlight their versatility, precision, and expanding role across modern medicine.
-
Spray Dried Biologics For Pulmonary Dosage Forms
Spray drying creates stable inhalable biologic powders with controlled particle size, enabling effective lung delivery, improved stability, and scalable production for respiratory and systemic therapies.
-
Spray Dried Biologics For Injectable Dosage Forms
Spray drying enables scalable production of stable, high‑concentration biologics as sterile powders, improving delivery, reducing costs, and overcoming limitations of traditional freeze‑drying methods.
FORMULATION DEVELOPMENT APPLICATIONS & STUDIES
-
Accelerated Yield Optimization Of Affinity Capture
High‑throughput affinity screening shows how buffer and pH optimization can boost AAV5 recovery, enabling faster, more reliable downstream process development for challenging serotypes.
-
Integrated Drug Discovery: Hit To PCC In 16 Months
Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.
-
From 51% Yield To 87% With Targeted Impurity Removal
Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.
-
Producing Quality APIs At Scale
Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development.
-
Native SEC-MALS Characterization Using A Chromatography Data System
Native SEC‑MALS offers a calibration‑free way to accurately characterize peptide oligomers, helping scientists distinguish true higher‑order structures while avoiding bias.
FORMULATION DEVELOPMENT SOLUTIONS
- High-Throughput Cellular Screening System
- Drug Product Services: Pre-Formulation To Commercial-Scale Production
- R&D And Analytical Services
- Oligonucleotide Discovery And Development
- Flow Process Technology
- Application Handbook, Chromatography Solutions For API Manufacturers
- MaxPeak Premier Columns For Protein SEC Analysis
- Double-Stranded mRNA Testing By ELISA
- Continuous Manufacturing
- Advancing Nitrosamine Testing For Evolving Regulations
PHARMACEUTICAL AND FORMULATION DEVELOPMENT NEWS
- Green Star Organic Milling Strengthens Food Safety Program With METTLER TOLEDO Metal Detector
- Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery
- Compact & Powerful Double Planetary Mixer For Lab And Pilot-Scaling
- METTLER TOLEDO Strengthens Its Portfolio In The Americas And Europe With Eagle
- AES Cleanroom Technology appoints John Groth As Chief Revenue Officer
- Navigating Change: Key Industry Insights At PHARMAP 2026
- AbbVie Announces $1.4 Billion North Carolina Campus To Expand U.S. Pharmaceutical Manufacturing Capacity
- Contec, Inc.® Partners With i-team Global To Deliver Cleanroom-Certified, Battery-Powered Mechanized Cleaning System
- MECART Releases Highlights Of Peer-Reviewed Study Assessing Cleanroom Life-Cycle Environmental Impacts
- CDMO Nucleus RadioPharma Secures $50 Million Financing From OrbiMed to Expand Manufacturing Capacity